Keyword: AstraZeneca

Move over, Roche. There’s a new small cell lung cancer therapy on the scene, and it belongs to AstraZeneca.

AstraZeneca has halted its phase 3 Farxiga trial in chronic kidney disease––a move that could soon spell an FDA approval in the major market.

AstraZeneca's Brilinta taken alone topped a Brilinta-asprin combo in reducing bleeding in a range of patient populations, according to new data.

AstraZeneca's Farxiga can help prevent worsening or death in heart failure patients regardless of other therapies received, according to new data.

Boehringer and Lilly's Jardiance is locked in a Type 2 diabetes battle against its SGLT2 rivals, and a leg up in Type 1 now doesn't appear likely.

Here’s a familiar sentence: A combo of Imfinzi and tremelimumab missed its primary endpoint. This time, it applies to a small-cell lung cancer trial.

Aiming to keep pace with its SGLT2 rivals in kidney disease, Lilly and Boehringer's Jardiance scored a speedy FDA review in the indication.

For AstraZeneca, 2019 was the year of the rebrand as it pivoted to cancer and rare diseases—and that shift yielded its CEO a 26% raise.

Imfinzi, given alone or in tandem with AZ's troubled CTLA4 tremelimumab, failed against chemo in first-line bladder cancer.

Doubling down on its asset-sale streak, AstraZeneca pawned off five of its hypertension meds to Atnahs Pharma for an upfront payment of $350 million.